Home/Pipeline/Anti-HBVxCD3

Anti-HBVxCD3

Chronic Hepatitis B (CHB)

PreclinicalActive

Key Facts

Indication

Chronic Hepatitis B (CHB)

Phase

Preclinical

Status

Active

Company

Ancora Bio

About Ancora Bio

Ancora Biotech is a strategic holding entity formed by former executives and investors of Teneobio to advance a portfolio of three multi-specific antibody programs. Its most advanced asset, TNB-486 (anti-CD19xCD3), is in Phase 1 for B-cell malignancies, while two preclinical programs target CD38 for metabolic diseases and HBVxCD3 for a functional cure of chronic hepatitis B. The company's model involves spinning out assets into dedicated subsidiaries (TeneoTwo, TeneoFour, TeneoTen) while centralizing oversight of manufacturing and clinical development. Key financial backers include Lightspeed Venture Partners and Sutter Hill Ventures.

View full company profile

Therapeutic Areas

Oncology Metabolic Diseases Infectious Diseases

Other Chronic Hepatitis B (CHB) Drugs

Drug	Company	Phase	Status
CARG-201	CaroGen	Pre-clinical	Active
Peginterferon-based therapies	Amoytop Biotech	Clinical	Multiple ongoing programs
VIR-2218 + VIR-3434	Vir Biotechnology	Phase 2	Active
Pevifoscorvir sodium (ALG-000184)	Aligos Therapeutics	Phase 2	Active
ALG-125755	Aligos Therapeutics	Phase 1	Status Unclear (Deprioritized)